MDVN Share Price

Open 81.44 Change Price %
High 81.48 1 Day 0.00 0.00
Low 81.43 1 Week 0.00 0.00
Close 81.44 1 Month 0.00 0.00
Volume 8577 1 Year 40.24 97.67
52 Week High 81.48
52 Week Low 26.41
MDVN Important Levels
Resistance 2 81.49
Resistance 1 81.47
Pivot 81.45
Support 1 81.41
Support 2 81.39
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Medivation, Inc. (NASDAQ: MDVN)

MDVN Technical Analysis 5
As on 27th Sep 2016 MDVN Share Price closed @ 81.44 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 52.27 & Strong Buy for SHORT-TERM with Stoploss of 71.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDVN Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MDVN Other Details
Segment EQ
Market Capital 3407713024.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.medivation.com
MDVN Address
MDVN
525 Market Street
36th Floor
San Francisco, CA 94105
United States
Phone: 415-543-3470
Fax: 415-543-3411
Interactive Technical Analysis Chart Medivation, Inc. ( MDVN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Medivation, Inc.
MDVN Business Profile
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies. The Company advanced program XTANDI (enzalutamide) capsules, or XTANDI, is partnered with Astellas Pharma Inc. ( Astellas). Together with Astellas, the Company is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. It also has ongoing programs with other agents in multiple different indications in early stages of research and development. The Company and Astellas also conduct the TERRAIN trial and the STRIVE trial, two randomized, double-blind Phase 2 trials evaluating enzalutamide head-to-head versus bicalutamide, the marketed anti-androgen drug, in pre-chemotherapy castration-resistant prostate cancer (CRPC patients).